Get a fresh start.
Add this topic to your myFT Digest for news straight to your inbox
German chemicals and pharma group has been under strain amid claims weedkiller causes cancer
Deal values BlueRock Therapeutics at $1bn
Welcome to Due Diligence, the FT’s daily deals briefing
With the disastrous purchase of Monsanto and plummeting shares, some question if it is time to break up the German group
Pharma and chemicals group says it will ‘defend itself vigorously’ amid mounting cases
Damages award reduced to $87m in partial victory for German chemicals company
Yellow Wood to snap up the maker of shoe inserts for almost $600m
Company calls decision ‘step in the right direction’ as it fights to limit damages
German group must first hose down its herbicide woes
Elliott welcomes shift as German chemicals group faces more than 13,000 glyphosate-related cases
The effort required does not justify the premium
Group’s €5bn investment on glyphosate alternatives is only tenth of annual research spending
Company mired in legal battles over glyphosate cancer allegations
The company’s case illustrates the danger of monopolising a market
BC Partners among those exploring bid for division that could fetch up to €8bn
A country that excels at innovation shrinks from the consequences of it
Group’s legal woes from $63bn Monsanto deal continue as cases and costs mount
The heightened trade war with China hands US stocks their biggest one-day drop in months
US jury awards sum to elderly couple over Monsanto product
External law firm hired to investigate allegations as scope of issue widens beyond France
Herbicide Roundup has brought legal troubles — and now plants are showing growing resistance to glyphosate
The German company missed a familiar risk in taking over Monsanto
A collector of vintage cars, Werner Baumann has seen his $63bn takeover of Monsanto backfire badly
Management teams are wrong to consider them ‘a complete waste of time’
